INR 61.06
(-0.33%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 16.2 Million INR | -25.66% |
2022 | 14 Million INR | -12.6% |
2021 | 16.01 Million INR | -25.02% |
2020 | 21.36 Million INR | -27.98% |
2019 | 29.66 Million INR | 19.73% |
2018 | 24.77 Million INR | 27.11% |
2017 | 19.49 Million INR | -25.24% |
2016 | 26.07 Million INR | 259.64% |
2015 | 7.24 Million INR | -26.9% |
2014 | 9.91 Million INR | -9.34% |
2013 | 10.93 Million INR | 26.45% |
2012 | 8.64 Million INR | 11.72% |
2011 | 7.74 Million INR | 195.19% |
2010 | -8.13 Million INR | -90.9% |
2009 | -4.26 Million INR | -157.79% |
2008 | 7.37 Million INR | 9.96% |
2007 | 6.7 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 2.81 Million INR | -7.16% |
2023 Q1 | 3.93 Million INR | -0.08% |
2023 Q3 | 4.83 Million INR | 28.38% |
2023 Q4 | 3.03 Million INR | -37.28% |
2023 FY | 10.4 Million INR | -25.66% |
2023 Q2 | 3.76 Million INR | -4.37% |
2022 Q2 | 3.27 Million INR | -13.31% |
2022 FY | 14 Million INR | -12.6% |
2022 Q4 | 3.93 Million INR | 30.35% |
2022 Q3 | 3.02 Million INR | -7.61% |
2022 Q1 | 3.77 Million INR | -68.67% |
2021 Q1 | 4.01 Million INR | -43.08% |
2021 FY | 16.01 Million INR | -25.02% |
2021 Q3 | 3.46 Million INR | -4.51% |
2021 Q2 | 3.63 Million INR | -9.54% |
2021 Q4 | 12.04 Million INR | 247.07% |
2020 Q4 | 7.05 Million INR | 55.59% |
2020 Q2 | 5.48 Million INR | 29.81% |
2020 Q3 | 4.53 Million INR | -17.27% |
2020 FY | 21.36 Million INR | -27.98% |
2020 Q1 | 4.22 Million INR | -59.16% |
2019 Q4 | 10.34 Million INR | 72.55% |
2019 FY | 29.66 Million INR | 19.73% |
2019 Q1 | 5.52 Million INR | -40.76% |
2019 Q2 | 7.14 Million INR | 29.21% |
2019 Q3 | 5.99 Million INR | -16.11% |
2018 Q4 | 9.33 Million INR | 80.49% |
2018 FY | 24.77 Million INR | 27.11% |
2018 Q1 | 4.77 Million INR | -55.04% |
2018 Q2 | 5.49 Million INR | 15.03% |
2018 Q3 | 5.17 Million INR | -5.87% |
2017 Q3 | 4.08 Million INR | 36.49% |
2017 Q1 | 1.8 Million INR | -81.83% |
2017 Q2 | 2.99 Million INR | 65.54% |
2017 FY | 19.49 Million INR | -25.24% |
2017 Q4 | 10.62 Million INR | 160.02% |
2016 Q3 | 7.27 Million INR | 6.01% |
2016 Q2 | 6.86 Million INR | 330.9% |
2016 Q1 | 1.59 Million INR | -86.75% |
2016 Q4 | 9.94 Million INR | 36.79% |
2016 FY | 26.07 Million INR | 259.64% |
2015 FY | 7.24 Million INR | -26.9% |
2015 Q3 | 3.47 Million INR | 16.29% |
2015 Q1 | 1.74 Million INR | 66.92% |
2015 Q2 | 2.98 Million INR | 70.81% |
2015 Q4 | 12.01 Million INR | 246.17% |
2014 Q2 | 1.95 Million INR | 296.15% |
2014 Q4 | 1.04 Million INR | -45.63% |
2014 FY | 9.91 Million INR | -9.34% |
2014 Q3 | 1.92 Million INR | -1.43% |
2014 Q1 | 493 Thousand INR | 160.05% |
2013 Q3 | 8.59 Million INR | 456.61% |
2013 Q1 | 1.62 Million INR | -65.81% |
2013 FY | 10.93 Million INR | 26.45% |
2013 Q2 | 1.54 Million INR | -4.75% |
2013 Q4 | -820.94 Thousand INR | -109.55% |
2012 Q1 | 1.68 Million INR | 184.58% |
2012 Q4 | 4.74 Million INR | 365.71% |
2012 FY | 8.64 Million INR | 11.72% |
2012 Q3 | 1.01 Million INR | -15.87% |
2012 Q2 | 1.21 Million INR | -28.06% |
2011 FY | 7.74 Million INR | 195.19% |
2011 Q4 | -1.98 Million INR | -224.44% |
2011 Q3 | 1.59 Million INR | 0.0% |
2010 FY | -8.13 Million INR | -90.9% |
2009 FY | -4.26 Million INR | -157.79% |
2008 FY | 7.37 Million INR | 9.96% |
2008 Q4 | 5.68 Million INR | 0.0% |
2007 FY | 6.7 Million INR | 0.0% |
2007 Q4 | 5.4 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Ajanta Pharma Limited | 30.46 Billion INR | 99.947% |
Amrutanjan Health Care Limited | 1.09 Billion INR | 98.525% |
Sigachi Industries Limited | 579.88 Million INR | 97.205% |
Bal Pharma Limited | 389.89 Million INR | 95.842% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 99.237% |
Medico Remedies Limited | 161.84 Million INR | 89.984% |
Lasa Supergenerics Limited | 291.17 Million INR | 94.433% |
Venus Remedies Limited | 1.91 Billion INR | 99.154% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 99.473% |
Alpa Laboratories Limited | 156.14 Million INR | 89.619% |
Nectar Lifesciences Limited | 625.55 Million INR | 97.409% |
Shilpa Medicare Limited | 2.18 Billion INR | 99.257% |
Aarti Drugs Limited | 1.16 Billion INR | 98.612% |
Lupin Limited | 95.67 Billion INR | 99.983% |
Aurobindo Pharma Limited | 39.23 Billion INR | 99.959% |
Zydus Lifesciences Limited | 43.17 Billion INR | 99.962% |
Windlas Biotech Limited | 1 Billion INR | 98.39% |
Suven Life Sciences Limited | 109.75 Million INR | 85.23% |
Eris Lifesciences Limited | 4.94 Billion INR | 99.672% |
Valiant Laboratories Limited | 36.28 Million INR | 55.332% |
J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 99.807% |
Solara Active Pharma Sciences Limited | 4.57 Billion INR | 99.646% |
Ipca Laboratories Limited | 13.91 Billion INR | 99.884% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 98.858% |
Achyut Healthcare Limited | 1.6 Million INR | -907.439% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.989% |
Bajaj HealthCare Limited | 985.34 Million INR | 98.355% |
RPG Life Sciences Limited | 1.63 Billion INR | 99.009% |
Mankind Pharma Limited | 23.15 Billion INR | 99.93% |
Laurus Labs Limited | 3.01 Billion INR | 99.462% |
Piramal Pharma Limited | 19.91 Billion INR | 99.919% |
Syncom Formulations (India) Limited | 942.39 Million INR | 98.28% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.924% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.898% |
Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 99.976% |
Unichem Laboratories Limited | 6.72 Billion INR | 99.759% |
Sequent Scientific Limited | 2.9 Billion INR | 99.441% |
Novartis India Limited | 470.1 Million INR | 96.552% |
Wanbury Limited | 1.16 Billion INR | 98.604% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 98.844% |
Wockhardt Limited | 6.4 Billion INR | 99.747% |
Themis Medicare Limited | 782.85 Million INR | 97.929% |
Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | 97.904% |
Jubilant Pharmova Limited | 14.45 Billion INR | 99.888% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 99.861% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.983% |
Divi's Laboratories Limited | 14.17 Billion INR | 99.886% |
NATCO Pharma Limited | 10.05 Billion INR | 99.839% |
Gufic Biosciences Limited | 1.07 Billion INR | 98.496% |
IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 98.525% |
Ind-Swift Limited | 946.56 Million INR | 98.288% |
Procter & Gamble Health Limited | 2.99 Billion INR | 99.459% |
FDC Limited | 5.34 Billion INR | 99.697% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | 64.881% |
Granules India Limited | 7.18 Billion INR | 99.774% |
Medicamen Biotech Limited | 335.16 Million INR | 95.164% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.951% |
AstraZeneca Pharma India Limited | 2.6 Billion INR | 99.377% |
Brooks Laboratories Limited | 51.18 Million INR | 68.328% |
Megasoft Limited | 49.52 Million INR | 67.272% |
ZIM Laboratories Limited | 1.01 Billion INR | 98.4% |
Strides Pharma Science Limited | 9.16 Billion INR | 99.823% |
Neuland Laboratories Limited | 2.92 Billion INR | 99.447% |
Morepen Laboratories Limited | 1.98 Billion INR | 99.184% |
Hikal Limited | 2.48 Billion INR | 99.348% |
Indoco Remedies Limited | 4.74 Billion INR | 99.659% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 99.473% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 96.07% |
Mangalam Drugs & Organics Limited | 676.14 Million INR | 97.603% |
Hester Biosciences Limited | 908.84 Million INR | 98.216% |